Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something?
Abstract Introduction: The anti-human globulin-enhanced complement-dependent cytotoxicity crossmatch (AHG-CDCXM) assay has been used to assess the presence of donor-specific antibodies (DSA) in recipient’s serum before kidney transplantation. The flow cytometric crossmatch (FCXM) assay was first i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Nefrologia
2021-04-01
|
| Series: | Brazilian Journal of Nephrology |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000300365&tlng=pt |
| _version_ | 1797205768565424128 |
|---|---|
| author | Jamile Abud Bruna Brasil Dal Pupo Cynthia da Silva Elizete Keitel Valter Duro Garcia Roberto Ceratti Manfro Jorge Neumann |
| author_facet | Jamile Abud Bruna Brasil Dal Pupo Cynthia da Silva Elizete Keitel Valter Duro Garcia Roberto Ceratti Manfro Jorge Neumann |
| author_sort | Jamile Abud |
| collection | DOAJ |
| description | Abstract Introduction: The anti-human globulin-enhanced complement-dependent cytotoxicity crossmatch (AHG-CDCXM) assay has been used to assess the presence of donor-specific antibodies (DSA) in recipient’s serum before kidney transplantation. The flow cytometric crossmatch (FCXM) assay was first introduced as an additional test. The aim of this study was to clinically validate the single use of the FCXM assay. Methods: This study compared the outcomes of a cohort of kidney transplant patients that underwent FCXM only (FCXM group) versus a cohort of kidney transplant patients that underwent AHG-CDCXM (control group). Results: Ninety-seven patients in the FCXM group and 98 controls were included. All crossmatches in the control group were negative. One patient in the FCXM group had a positive B cell crossmatch. One year after transplantation, there were no significant differences in patient survival (p = 0.591) and graft survival (p = 0.692) between the groups. Also, no significant difference was found in the incidence of Banff ≥ 1A acute cellular rejection episodes (p = 0.289). However, acute antibody-mediated rejections occurred in 3 controls (p = 0.028). Conclusion: The results showed that discontinuing the AHG-CDCXM assay does not modify the clinical outcomes in a 1-year follow-up. |
| first_indexed | 2024-04-24T08:56:22Z |
| format | Article |
| id | doaj.art-caf00f0e8633446e84b08fe13b21d214 |
| institution | Directory Open Access Journal |
| issn | 2175-8239 |
| language | English |
| last_indexed | 2024-04-24T08:56:22Z |
| publishDate | 2021-04-01 |
| publisher | Sociedade Brasileira de Nefrologia |
| record_format | Article |
| series | Brazilian Journal of Nephrology |
| spelling | doaj.art-caf00f0e8633446e84b08fe13b21d2142024-04-16T07:36:54ZengSociedade Brasileira de NefrologiaBrazilian Journal of Nephrology2175-82392021-04-0143336537410.1590/2175-8239-jbn-2019-0222Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something?Jamile Abudhttps://orcid.org/0000-0002-9176-0464Bruna Brasil Dal Pupohttps://orcid.org/0000-0002-4211-4845Cynthia da Silvahttps://orcid.org/0000-0002-3778-4473Elizete Keitelhttps://orcid.org/0000-0002-5519-8224Valter Duro Garciahttps://orcid.org/0000-0002-7394-1501Roberto Ceratti Manfrohttps://orcid.org/0000-0001-8324-3734Jorge Neumannhttps://orcid.org/0000-0002-1923-8348Abstract Introduction: The anti-human globulin-enhanced complement-dependent cytotoxicity crossmatch (AHG-CDCXM) assay has been used to assess the presence of donor-specific antibodies (DSA) in recipient’s serum before kidney transplantation. The flow cytometric crossmatch (FCXM) assay was first introduced as an additional test. The aim of this study was to clinically validate the single use of the FCXM assay. Methods: This study compared the outcomes of a cohort of kidney transplant patients that underwent FCXM only (FCXM group) versus a cohort of kidney transplant patients that underwent AHG-CDCXM (control group). Results: Ninety-seven patients in the FCXM group and 98 controls were included. All crossmatches in the control group were negative. One patient in the FCXM group had a positive B cell crossmatch. One year after transplantation, there were no significant differences in patient survival (p = 0.591) and graft survival (p = 0.692) between the groups. Also, no significant difference was found in the incidence of Banff ≥ 1A acute cellular rejection episodes (p = 0.289). However, acute antibody-mediated rejections occurred in 3 controls (p = 0.028). Conclusion: The results showed that discontinuing the AHG-CDCXM assay does not modify the clinical outcomes in a 1-year follow-up.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000300365&tlng=ptFlow CytometryCytotoxicity Tests, ImmunologicGraft RejectionTransplante. |
| spellingShingle | Jamile Abud Bruna Brasil Dal Pupo Cynthia da Silva Elizete Keitel Valter Duro Garcia Roberto Ceratti Manfro Jorge Neumann Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? Brazilian Journal of Nephrology Flow Cytometry Cytotoxicity Tests, Immunologic Graft Rejection Transplante. |
| title | Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
| title_full | Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
| title_fullStr | Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
| title_full_unstemmed | Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
| title_short | Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
| title_sort | phasing out the pre transplant cytotoxicity crossmatch are we missing something |
| topic | Flow Cytometry Cytotoxicity Tests, Immunologic Graft Rejection Transplante. |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000300365&tlng=pt |
| work_keys_str_mv | AT jamileabud phasingoutthepretransplantcytotoxicitycrossmatcharewemissingsomething AT brunabrasildalpupo phasingoutthepretransplantcytotoxicitycrossmatcharewemissingsomething AT cynthiadasilva phasingoutthepretransplantcytotoxicitycrossmatcharewemissingsomething AT elizetekeitel phasingoutthepretransplantcytotoxicitycrossmatcharewemissingsomething AT valterdurogarcia phasingoutthepretransplantcytotoxicitycrossmatcharewemissingsomething AT robertocerattimanfro phasingoutthepretransplantcytotoxicitycrossmatcharewemissingsomething AT jorgeneumann phasingoutthepretransplantcytotoxicitycrossmatcharewemissingsomething |